TI - Optimizing Patient Selection for Bevacizumab Plus Irinotecan in Recurrent High Grade Glioma: Superiority of the Neutrophil-to-Lymphocyte Ratio Over Other Systemic Inflammation Indices
PT - Journal Article
DP - 2026
TA - EJMI
PG - 37-45
VI - 10
IP - 1
AID - 263037 [doi]
4100 - https://dx.doi.org/10.14744/ejmi.263037
SO - EURASIAN JOURNAL OF MEDICIAL INVESTIGATION,2026 10(1): 37